Search Contract Opportunities

Vape Inspection

ID: 75F40123R00049 • Type: Solicitation • Match:  95%
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Do the documents mention an incumbent contractor?
I'd like to anonymously submit a question to the procurement officer(s)
Loading

Description

Posted: July 14, 2023, 7:00 p.m. EDT

See attached amendment for RFP and responses to questions.

Posted: June 29, 2023, 6:06 p.m. EDT
Background
The solicitation is for a Vape Inspection contract under the Family Smoking Prevention and Tobacco Control Act, which grants the Food and Drug Administration (FDA) authority to regulate the manufacturing, marketing, and distribution of tobacco products to protect public health and reduce tobacco use by minors. The contract aims to inspect establishments engaged in the manufacture, assembly, preparation, compounding, processing, packing, or repacking, labeling, or relabeling, or holding of regulated tobacco products to document compliance with certain provisions of the FD&C Act.

Work Details
The contractor will provide Vape Inspections to inspect establishments engaged in the manufacture, assembly, preparation, compounding, processing, packing, or repacking, labeling, or relabeling, or holding of regulated tobacco products (manufacturers) to document compliance with certain provisions of the FD&C Act. The contract term is a total of five (5) years with five (5) one-year ordering periods. The contract will be for Commercial Services, IDIQ contract firm fixed unit prices (labor rates), and cost reimbursement line items for other direct costs and travel. The Contractor shall be capable of employing individuals who are eligible to be commissioned in accordance with Section 702(a)(1)(A) of the FD&C Act.

Period of Performance
The Period of Performance for the contract is from 09/10/2023 to 09/09/2028. Additionally, there are specific periods of performance for each task: Year 1: 09/10/2023 - 09/09/2024; Year 2: 09/10/2024 - 09/09/2025; Year 3: 09/10/2025 - 09/09/2026; Year 4: 09/10/2026 - 09/09/2027; Year 5: 09/10/2027 - 09/09/2028.

Overview

Response Deadline
July 19, 2023, 2:00 p.m. EDT Past Due
Posted
June 29, 2023, 6:06 p.m. EDT (updated: July 14, 2023, 7:00 p.m. EDT)
Set Aside
Women-Owned Small Business (WOSB)
Place of Performance
Beltsville, MD 20705 United States
Source

Current SBA Size Standard
$19.5 Million
Pricing
Multiple Types Common
Evaluation Criteria
Best Value
Est. Level of Competition
Average
Vehicle Type
Indefinite Delivery Contract
Signs of Shaping
61% of obligations for similar contracts within the Food and Drug Administration were awarded full & open.
On 6/29/23 FDA Office of Acquisition and Grant Services issued Solicitation 75F40123R00049 for Vape Inspection due 7/19/23. The opportunity was issued with a Women-Owned Small Business (WOSB) set aside with NAICS 541990 (SBA Size Standard $19.5 Million) and PSC H399.
Primary Contact
Name
Janice Heard   Profile
Phone
(215) 717-3093
Fax
(215) 597-6649

Documents

Posted documents for Solicitation 75F40123R00049

Question & Answer

The AI Q&A Assistant has moved to the bottom right of the page

IDV Awards

Indefinite delivery vehicles awarded through Solicitation 75F40123R00049

Incumbent or Similar Awards

Contracts Similar to Solicitation 75F40123R00049

Potential Bidders and Partners

Awardees that have won contracts similar to Solicitation 75F40123R00049

Similar Active Opportunities

Open contract opportunities similar to Solicitation 75F40123R00049

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > FOOD AND DRUG ADMINISTRATION > FDA Office of Acquisitions and Grants Services
FPDS Organization Code
7524-75FDA1
Source Organization Code
500035507
Last Updated
July 20, 2023
Last Updated By
janice.heard@fda.hhs.gov
Archive Date
July 20, 2023